Table 2.
Comparison of Sensitivity of T-SPOT.TB Versus QuantiFERON-TB Gold In-Tube Among Persons With Suspected Active Tuberculosis
| Author, year | Country | HIV status | Active tuberculosis, n (%) | Positive T-SPOT result, n (%) | Positive QFT-GIT result, n (%) | Sensitivity differencea (%) |
| Dheda, 2009b | South Africa | HIV− | 15 (31), 15 (29) | 14 (93) | 11 (73) | 20 |
| Dheda, 2009 | South Africa | HIV+ | 5 (25) | 5 (100) | 1 (20) | 80 |
| Leidl, 2009 | Uganda | HIV+ | 19 (15) | 17 (89) | 14 (74) | 15 |
| Markova, 2009 | Bulgaria | HIV+ | 13 (14) | 8 (62) | 12 (92) | −31 |
Abbreviations: HIV, human immunodeficiency virus; QFT-GIT, QuantiFERON-TB Gold In-Tube; T-SPOT, T-SPOT.TB.
a
Sensitivity difference (%) is T-SPOT sensitivity (%)−QFT-GIT sensitivity (%).
b
Total number of active tuberculosis suspects evaluated by each interferon-γ release assay differed within some studies; these are listed in the order T-SPOT, QFT-GIT.